中银国际发表报告指，锦欣生殖(01951.HK) 2024年业绩不佳，总收入按年增长1%，IVF周期数按年下降6%，净利润按年下降18%，低于市场预期。管理层表示，辅助生殖纳入医保报销迄今为止对业务的积极影响有限。管理层没有提供2025年的增长指引，主要是因为中国辅助生殖业务前景不明朗。在海外，管理层优先考虑销量和市场份额增长，而不是短期盈利能力。业绩公布后，中银国际下调对锦欣生殖的销售额，原因是...
Source Link中银国际发表报告指，锦欣生殖(01951.HK) 2024年业绩不佳，总收入按年增长1%，IVF周期数按年下降6%，净利润按年下降18%，低于市场预期。管理层表示，辅助生殖纳入医保报销迄今为止对业务的积极影响有限。管理层没有提供2025年的增长指引，主要是因为中国辅助生殖业务前景不明朗。在海外，管理层优先考虑销量和市场份额增长，而不是短期盈利能力。业绩公布后，中银国际下调对锦欣生殖的销售额，原因是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.